Research and Development Fee. Arcadia provided minimum funding in the amount of [...*...] to Xxxxxx between 2003 and 2005 for research under the Research Plan related to broadening and strengthening of Xxxxxx Co-Owned or Xxxxxx Only Patents on genes used for the production of GLA, DGLA, and/or ARA in plants. An initial payment of [...*...] was paid to Xxxxxx upon […*…] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. signing of the Original Agreement and other payments were made as described in the Research Plan.
Research and Development Fee. To reimburse Abbott for its participation in the Project, InterMune shall pay Abbott a [*] research and development fee [*]. The research and development fee (“Fee”) shall be paid to Abbott as follows:
Research and Development Fee. To reimburse Abbott for its participation in the Project in compliance with the activities described therein and in, this Agreement, and in accordance with the Delivery and Payment Schedule set forth in Exhibit C, ZymoGenetics shall pay Abbott a [ * ] (except as set forth in Section 12.6(f)) research and development fee (“Research and Development Fee”), which fee in the aggregate upon completion of the Project may be less than or equal to, but shall not exceed, [ * ], unless revisions occur in the Project scope in accordance with the terms of this Article 5. The Parties understand and agree that the Research and Development Fee is composed of, in part, by the Reservation Rate described in Section 2.3. The Research and Development Fee, shall be paid to Abbott as outlined in the Delivery and Payment Schedule identified in the Project (Exhibit C). Any such modifications agreed upon by the Parties to the scope of the Project shall be incorporated into the Payment Schedule by a written agreement between ZymoGenetics and Abbott.
Research and Development Fee. 2.1 In consideration of performing the Work, Party A shall reimburse Party B for all necessary and reasonable direct and indirect costs incurred by Party B in the performance of its duties under this Agreement including, without limitation, the appropriate portion of Party B’s occupancy costs, employee salaries, overhead, travel expenses, and professional fees plus five percent (5%) of such costs (the “R&D Fee”). These costs shall include value-added and other indirect taxes levied on Party B, and shall be calculated in accordance with generally accepted accounting principles.
Research and Development Fee. To reimburse Abbott for its participation in the Project in compliance with the activities described therein and in this Agreement, and in accordance with the Payment Schedule, Seattle Genetics shall pay Abbott a research and development fee (“Research and Development Fee”), which fee in the aggregate upon completion of the Project may be [***], but shall not [***], unless revisions occur in the Project scope in accordance with the terms of this Article 5. The maximum [***] of [***] the costs for the services to be performed [***] and the raw materials, resins, disposable process components, reagents and testing supplies which are currently [***]; provided, however, that if the costs of raw materials, resins, disposable process components, reagents and testing supplies [***], Seattle Genetics shall[***] for those excess costs and the Research and Development Fee shall be [***] by the [***] of those excess costs. The Parties understand and agree that the Research and Development Fee is comprised of, in part, on a [***], the [***] described in Section 2.3. The Research and Development Fee shall [***] to Abbott as outlined in the Payment Schedule. Any such modifications agreed upon by the Parties to the scope of the Project shall be incorporated into the Payment Schedule by a written agreement between Seattle Genetics and Abbott.
Research and Development Fee. In consideration of select activities that Abbott shall perform under Articles 3 and 4 hereof, Versicor shall pay Abbott a non-refundable research and development fee of [**] U.S. Dollars (U.S. $[**]). In the event that Abbott does not receive complete, validated reference standards in Abbott specified amounts from Xxx Lilly or other third parties, and it becomes necessary for Abbott to perform additional research and development, Versicor shall pay to Abbott an amount, not to exceed [**] U.S. Dollars (U.S. $[**]) as set forth on Exhibit D. This “not to exceed” amount is currently reflected in Exhibit E. The total research and development fees charged to Versicor under this Agreement shall not exceed [**] U.S. Dollars (U.S. $[**]), excluding all raw materials other than [**] and additional charges, if any, incurred pursuant to Sections 5.2 and 5.3 below. Unless instructed by Versicor, the total fees to be paid by Versicor under Exhibit E in Contract Years [**] shall not exceed the amounts set forth therein. If reference standard production fees are incurred in [**], Abbott shall adjust other fees accordingly to assure that the total annual charges do not exceed the total annual charges set forth in Exhibit E. The parties shall agree to any additional changes in the research and development scope and commercial production activities that are not covered herein. The research and development fee shall be paid to Abbott in accordance with Exhibit E.
Research and Development Fee. To reimburse Abbott for its participation in the product development project, Pharmacyclics shall pay to Abbott a non-refundable (subject to Section 11.2 hereof) research and development fee of [***] for Abboxx'x xxxearch efforts relating to the [***] Delivery Systems only. The research and development fee shall be paid to Abbott according to the following milestones; provided, however, if Abbott does not achieve certain milestones below, no payments shall be due for such milestone:
Research and Development Fee. To reimburse Abbott for its participation in the Project in compliance with the activities described therein and in this Agreement, and in accordance with the Payment Schedule, Seattle Genetics shall pay Abbott a research and development fee (“Research and Development Fee”), which fee in the aggregate upon completion of the Project may be [*], but shall not [*], [*], unless revisions occur in the Project scope in accordance with the terms of this Article 5. The Parties understand and agree that the Research and Development Fee is comprised of, in part, on a dollar for dollar basis, the [*] described in Section 2.3. The Research and Development Fee shall be paid to Abbott as outlined in the Payment Schedule. Any such modifications agreed upon by the Parties to the scope of the Project shall be incorporated into the Payment Schedule by a written agreement between Seattle Genetics and Abbott.
Research and Development Fee. To reimburse Abbott for its participation in the Project in compliance with the activities described therein and in this Agreement, and in accordance with the Payment Schedule, Seattle Genetics shall pay Abbott a research and development fee (“Research and Development Fee”), which fee in the aggregate upon completion of the Project may be less than or equal to, but shall not exceed, Seven Million Eight Hundred Ninety Thousand Dollars (U.S.$7,890,000), unless revisions occur in the Project scope in accordance with the terms of this Article 5. The Parties understand and agree that the Research and Development Fee is comprised of, in part, on a dollar for dollar basis, the Reservation Rate described in Section 2.3. The Research and Development Fee shall be paid to Abbott as outlined in the Payment Schedule. Any such modifications agreed upon by the Parties to the scope of the Project shall be incorporated into the Payment Schedule by a written agreement between Seattle Genetics and Abbott.
Research and Development Fee. The parties acknowledge and agree that Abbott has been paid in full for its participation in the Project for Stages 1 – 3 of the Project. The parties further agree that to reimburse Abbott for its participation in the Stage 4 Project, Targanta shall pay Abbott a [*] research and development fee [*] (the “Fee”). The Fee shall be paid on a [*] basis as broken down in the Payment Schedule Forecast set forth in Exhibit C and is mutually exclusive and in addition to the research and development fee already paid by InterMune for the completion of Stages 1, 2, and 3. Invoices shall be sent to Targanta on a [*] basis and payment for the applicable Fee for that period shall be made within [*] of receipt of each applicable invoice. If milestones in the Stage 4 Project are reached earlier than forecasted, the Stage 4 Project will move to the next area of focus with a commensurate reduction in the forecasted fees, if applicable, and any such adjusted fee shall be set forth in writing.
